BACKGROUND HER‐2/neu tissue overexpression is found in nearly 15% of patients with
nonsmall cell lung carcinoma and is reported to affect prognosis adversely in surgical series …

BACKGROUND Using immunohistochemistry, the authors prospectively investigated the
expression of HER‐2/neu protein in radically resected specimens of nonsmall cell lung …

Major prognostic factors for early-stage non–small-cell lung cancer (NSCLC) are tumor size
and nodal status. It has been suggested that HER2/neu overexpression may be related to …

Background Recent studies imply that HER2/neu is a potential prognostic factor in patients
with non–smallcell lung cancer (NSCLC). Whereas considerable evidence indicates sex …

Despite intensive treatment efforts, the prognosis for lung cancer is very poor; less than 15%
of patients survive 5 years. Trastuzumab, a monoclonal antibody targeting the HER2/neu …

Background and objectives Lung cancer is the most common cause of cancer‐related death
worldwide in both sexes. Evidence suggests the role of genetic factors in lung cancer …

Purpose: Amplification and/or overexpression of HER2/neu have been documented in many
types of epithelial tumor, and HER2/neu evaluation is now gaining importance, because this …

Abstract Background. HER‐2/neu gene amplification and protein overexpression have been
identified in various solid tumors, but its prognostic relevance in head and neck squamous …

BACKGROUND:: Expression and amplification of the HER2/neu protooncogene was
analyzed in locally advanced NSCLC in a multimodality therapy approach in order to obtain …

HER‐2/neu oncogene activation by either gene amplification and/or protein overexpression
has been documented in several human malignancies. Irrespective of protein …